LexDanaLexDanabeta
Inventor

Bingsong Han

Inventor
Westwood, MA, US

Overview

53→
Patents
2005–2020
Patent span
Human necessities
Primary field (CPC A)

Patents· 53 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations29%
C07DHeterocyclic compounds29%
A61KPreparations for medical, dental or toiletry purposes23%
Y02ATechnologies for adaptation to climate change16%
C07CAcyclic or carbocyclic compounds4%
A01NPreservation of bodies of humans or animals or plants or parts thereof1%
PatentTitleYear
10,829,4613-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors202010,829,4623-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors202010,829,460[6,6] fused bicyclic HDAC8 inhibitors202010,822,3163-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors202010,772,874Compounds and compositions for the inhibition of NAMPT202010,696,692Amido-benzyl sulfone and sulfoxide derivates202010,647,695Compounds and compositions for the inhibition of NAMPT202010,538,496Methods using HDAC11 inhibitors202010,513,5013-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,508,088Methods using HDAC11 inhibitors201910,508,077Alpha-cinnamide compounds and compositions as HDAC8 inhibitors201910,501,4243-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,494,3543-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,494,3533-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,494,3523-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,494,3513-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,479,7723-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,472,3373-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,464,9093-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,464,9103-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,456,382Compounds and compositions for the inhibition of NAMPT201910,457,6523-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,450,2833-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,450,2843-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,442,7763-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,428,0313-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,421,7313-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,421,7323-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,414,7383-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,377,7263-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,370,343[6,6] Fused bicyclic HDAC8 inhibitors201910,329,275Compounds and compositions for the inhibition of NAMPT201910,272,072Compounds and compositions for the inhibition of NAMPT201910,266,487Alpha-cinnamide compounds and compositions as HDAC8 inhibitors201910,239,8453-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,214,5013-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,214,5003-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,112,9153-aryl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201810,029,995[6,6] fused bicyclic HDAC8 inhibitors20189,745,253'Alpha-cinnamide compounds and compositions as HDAC8 inhibitors'20179,676,721'Compounds and compositions for the inhibition of NAMPT'20179,637,453'3-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitors'20179,630,922'3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors'20179,555,039'Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)'20179,169,209'Compounds and compositions for the inhibition of NAMPT'20158,119,665'Aryl imidazoles and related compounds as C5a receptor modulators'20127,851,474'Dipiperazinyl ketones and related analogues'20107,795,262'Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues'20107,351,826'Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds'20087,271,170'Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands'20077,122,546'Imidazol-1-ylmethyl pyridazine derivatives'20067,030,144'Substituted imidazole derivatives: GABAA receptor ligands'20066,951,864'4-imidazol-1-ylmethyl-pyrimidine derivatives'2005

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2005–2010Patents assigned to NEUROGEN CORP (7)· patent assignee history
2005–2012Based in Hamden, CT, US· patent location history
2007–2019Based in North Haven, CT, US· patent location history
2012–2017Patents assigned to HAN BINGSONG (4)· patent assignee history
2015–2020Patents assigned to FORMA TM LLC (9)· patent assignee history
2017–2020Patents assigned to FORMA THERAPEUTICS INC (32)· patent assignee history
2017–2020Based in Watertown, MA, US· patent location history
2019–2020Patents assigned to GENENTECH INC (6)· patent assignee history
2019–2020Based in Westwood, MA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
FORMA THERAPEUTICS INC322017–2020
FORMA TM LLC92015–2020
NEUROGEN CORP72005–2010
GENENTECH INC62019–2020
HAN BINGSONGself42012–2017
Locations
LocationPatentsSpan
Westwood, Massachusetts, US282019–2020
North Haven, CT, US192007–2019
Hamden, CT, US42005–2012
Watertown, Massachusetts, US22017–2020